8-K: Cassava Sciences Announces Executive Changes: CMO Retirement and New SVP of Clinical Development

Cassava Sciences announces the retirement of Chief Medical Officer James W. Kupiec, effective May 9, 2025, and the appointment of Jack Moore as Senior Vice President, Clinical Development, starting April 28, 2025.

Summary

• Cassava Sciences announced the retirement of its Chief Medical Officer, James W. Kupiec, effective May 9, 2025.
• Jack Moore, PhD, has been appointed as Senior Vice President, Clinical Development, effective April 28, 2025.
• Moore will be responsible for advancing the clinical evaluation of simufilam in new potential indications, including tuberous sclerosis complex (TSC).
• R. Christopher Cook was appointed Chief Operating and Legal Officer of the Company on April 18, 2025.
• Cook's base salary increased from $438,000 to $475,000, with an annual bonus target of 40% of his base salary.
• Eric J. Schoen's employment agreement was also amended and restated, with his base salary remaining unchanged and an annual bonus target of 40% of his base salary.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the planned executive transition and the appointment of an experienced clinical development leader. The company is also exploring new indications for its drug candidate, which could be a positive catalyst. However, the inherent risks in drug development temper the overall sentiment.

Positives

• The appointment of Jack Moore as SVP of Clinical Development brings extensive experience in CNS and neurodegenerative diseases.
• Moore's expertise is expected to be valuable as Cassava Sciences explores additional potential applications for simufilam.
• Christopher Cook's promotion to Chief Operating and Legal Officer recognizes his contributions to the company.
• The amended employment agreements provide clarity and stability for key executives.

Negatives

• The retirement of James W. Kupiec, while planned, represents a loss of expertise in Alzheimer's disease drug development.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the ability to advance preclinical studies related to TSC-related epilepsy.
• The success of simufilam in new indications is not guaranteed.
• Clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval.

Future Outlook

Cassava Sciences plans to conduct preclinical studies of simufilam relating to seizures in TSC and explore additional potential applications for the drug.

Management Comments

• 'The entire Cassava team is grateful for Jim's service as our Chief Medical Officer,' said Rick Barry, President and Chief Executive Officer of Cassava.
• Rick Barry stated that Jack Moore's skills will be invaluable as they take the next steps in their TSC program, identify potential clinical collaborators and study sites, and explore additional potential applications.
• Dr. Jack Moore stated he is eager to contribute his clinical development expertise to Cassava's emerging program for simufilam in TSC and other applications.

Industry Context

The appointment of a new SVP of Clinical Development with experience in CNS disorders suggests a strategic shift towards expanding the applications of simufilam beyond Alzheimer's disease, potentially targeting a broader range of neurological conditions.

Comparison to Industry Standards

• Executive compensation packages, including base salary and bonus targets, are generally in line with industry standards for biotechnology companies of similar size and stage of development.
• Companies like Alector Inc., Novartis Pharmaceuticals Corporation, and Bristol-Myers Squibb Company (Celgene Corporation) are examples of large pharmaceutical companies where Jack Moore previously held leadership roles, indicating a high level of experience and expertise.
• The severance terms outlined in the employment agreements, including continued salary and benefits for 12 months upon termination without cause, are typical for executive-level positions.

Management Changes

Stakeholder Impact

• Shareholders may view the executive changes as a strategic move to expand the company's focus and pipeline.
• Employees may experience changes in reporting structures and responsibilities due to the management changes.
• Patients with TSC-related epilepsy may benefit from the company's efforts to develop simufilam for this indication.

Next Steps

• Advance preclinical studies related to TSC-related epilepsy.
• Identify potential clinical collaborators and study sites for simufilam in TSC and other applications.
• Explore additional potential applications for simufilam.

Key Dates

Keywords

Cassava Sciences, simufilam, clinical development, executive changes, Chief Medical Officer, Chief Operating Officer, Alzheimer's disease, tuberous sclerosis complex, CNS disorders, biotechnology